Johannes Fosselteder
Overview
Explore the profile of Johannes Fosselteder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sconocchia T, Fosselteder J, Sconocchia G, Reinisch A
Front Immunol
. 2023 Nov;
14:1275085.
PMID: 37965340
Langerhans cell histiocytosis (LCH) is a rare and clinically heterogeneous hematological disease characterized by the accumulation of mononuclear phagocytes in various tissues and organs. LCH is often characterized by activating...
2.
Sconocchia T, Fosselteder J, Auinger L, Ozkaya E, Benezeder T, Lang M, et al.
Leukemia
. 2023 Sep;
37(11):2292-2296.
PMID: 37673974
No abstract available.
3.
Sconocchia T, Fosselteder J, Kohnke T, Majeti R, Reinisch A
J Vis Exp
. 2023 Mar;
(193).
PMID: 36971438
Throughout their lifetime, hematopoietic stem and progenitor cells (HSPCs) acquire somatic mutations. Some of these mutations alter HSPC functional properties such as proliferation and differentiation, thereby promoting the development of...
4.
Fosselteder J, Pabst G, Sconocchia T, Schlacher A, Auinger L, Kashofer K, et al.
Leukemia
. 2023 Feb;
37(4):843-853.
PMID: 36813992
Calreticulin (CALR) mutations present the main oncogenic drivers in JAK2 wildtype (WT) myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where mutant (MUT) CALR is increasingly recognized as a suitable...
5.
Thompson-Peach C, Fosselteder J, Reinisch A, Thomas D
Bio Protoc
. 2023 Feb;
13(2):e4592.
PMID: 36789162
Primary hematopoietic stem and progenitor cell (HSPC)-derived megakaryocytes are a valuable tool for translational research interrogating disease pathogenesis and developing new therapeutic avenues for patients with hematologic disorders including myeloproliferative...
6.
Tvorogov D, Thompson-Peach C, Fosselteder J, Dottore M, Stomski F, Onnesha S, et al.
EMBO Rep
. 2022 Feb;
23(4):e52904.
PMID: 35156745
Calreticulin (CALR) is recurrently mutated in myelofibrosis via a frameshift that removes an endoplasmic reticulum retention signal, creating a neoepitope potentially targetable by immunotherapeutic approaches. We developed a specific rat...
7.
Jensen T, Mikkelsen N, Gao Z, Fosselteder J, Pabst G, Axelgaard E, et al.
Genome Res
. 2021 Aug;
31(11):2120-2130.
PMID: 34407984
Targeted transcriptional activation or interference can be induced with the CRISPR-Cas9 system (CRISPRa/CRISPRi) using nuclease-deactivated Cas9 fused to transcriptional effector molecules. These technologies have been used in cancer cell lines,...
8.
Alkan H, Vesely P, Hackl H, Fosselteder J, Schmidt D, Vander Heiden M, et al.
Cancer Metab
. 2020 Dec;
8(1):26.
PMID: 33292758
Background: Aspartate biosynthesis and its delivery to the cytosol can be crucial for tumor growth in vivo. However, the impact of intracellular aspartate levels on metastasis has not been studied....
9.
Seles M, Hutterer G, Fosselteder J, Svoboda M, Resel M, Barth D, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32397610
POU3F3 adjacent non-coding transcript 1 (PANTR1) is an oncogenic long non-coding RNA with significant influence on numerous cellular features in different types of cancer. No characterization of its role in...
10.
Fosselteder J, Calin G, Pichler M
Expert Opin Ther Targets
. 2018 Oct;
22(12):973-976.
PMID: 30365347
No abstract available.